Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 11/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 10/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | CDK7 | P50613 | 4/20 | 0.39 |
| ▸ | CCNH | P51946 | 4/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 4/20 | 0.39 |
| ▸ | CCNK | O75909 | 3/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22200720 | 0.89 | HDAC3 (0.38) | MAPK8MAPK10MAPK9CCNA2CDK2 | |
| SCHEMBL29354891 | 0.89 | HDAC3 (0.38) | MAPK8MAPK10MAPK9CCNA2CDK2 | |
| SCHEMBL22190697 | 0.85 | MAPK8 (0.45) | MAPK8MAPK10MAPK9CCNA2CDK2 | |
| SCHEMBL29356361 | 0.85 | ERN1 (0.46) | MAPK8MAPK10MAPK9CCNA2CDK2 | |
| SCHEMBL22200542 | 0.85 | ERN1 (0.46) | MAPK8MAPK10MAPK9CCNA2CDK2 | |
| SCHEMBL22200705 | 0.83 | ERN1 (0.48) | MAPK8CDK2ALDH1A1CYP1A2TSHR | |
| SCHEMBL29356760 | 0.83 | ERN1 (0.48) | MAPK8CDK2ALDH1A1CYP1A2TSHR | |
| SCHEMBL29357908 | 0.81 | ERN1 (0.54) | MAPK8MAPK10MAPK9CDK2ALDH1A1 | |
| SCHEMBL22200541 | 0.81 | ERN1 (0.54) | MAPK8MAPK10MAPK9CDK2ALDH1A1 | |
| SCHEMBL22200342 | 0.80 | ERN1 (0.63) | MAPK8CDK2ALDH1A1CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113508115-A | Pyridopyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme I (IRE I A) for the treatment of cancer diseases | 基因泰克公司 | 2021-10-15 | — | — | CN | disclosed |
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | MAPK8 925/4885MAPK10 3731/4885MAPK9 3080/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | MAPK8 925/4885MAPK10 3731/4885MAPK9 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.